Clene to Meet with FDA to Discuss ALS Treatment Development
Clene Inc. will hold a crucial meeting with the FDA to discuss the development of CNM-Au8 for treating amyotrophic lateral sclerosis (ALS). This meeting signifies potential progress in addressing a devastating neurodegenerative disease.
Read the full story


























